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Abstract
Cerebral microvascular endothelial cells—coming in contact with pericytes
and astrocytes—constitute the structural basis of the blood-brain barrier
(BBB). The continuous belt of interendothelial tight junctions (TJs) and the
presence of specific transport systems, enzymes, and receptors in the brain
endothelium regulate the molecular and cellular traffic into the central
nervous system. Pituitary adenylate cyclase-activating polypeptide
(PACAP) is a neuropeptide having several cellular protective effects.
However, little is known about the effects of PACAP on the cerebral
endothelium and BBB functions. Here, we show that PACAP has no
significant pro-survival role in cerebral microvascular endothelial cells;
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however, it improves the barrier properties of the brain endothelium.
PACAP induces an increase in the transendothelial electrical resistance,
which is the most important marker of the tightness of the TJs. Moreover,
PACAP has a protective role against glucose deprivation- and oxidative
stress-induced junctional damage in microvascular brain endothelial cells.
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Introduction
Neurons of the vertebrate brain require strictly regulated concentrations of
ions, neurotransmitters, hormones, and other biologically active substances.
The blood-brain barrier (BBB) is one of the most important systems
responsible for the maintenance of this microenvironment. The BBB is formed
by brain capillary endothelial cells in close association with pericytes and
astrocytic end feet almost completely covering the cerebral surface of the
endothelium. In comparison to endothelia of non-cerebral origin, brain
endothelia undergo an additional step of differentiation which results in a
specific cellular phenotype that resembles epithelial cells. In this respect, the
most prominent feature of cerebral endothelial cells is the occurrence of
continuous tight junctions (TJs) which seal the paracellular passage for
macromolecules and cells from the blood stream into the brain parenchyma.
Other characteristics specific to cerebral endothelial cells include the absence
of fenestrations, the paucity of pinocytotic vesicles, the high number of
mitochondria, and a variety of transport systems in the luminal and abluminal
cellular membrane (for review see: Abbott et al. 2010 ; Wilhelm et al. 2011 ).
Tight junctions regulate the paracellular permeability of the endothelial layer
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and also organize the polarization of the endothelial cell membrane separating
an apical and a basolateral surface. By regulating the traffic of ions, tight
junctions are responsible for establishing the transendothelial electrical
resistance (TEER) between the apical and basolateral side of the cells. Tight
junctions are composed of transmembrane proteins, including occludin,
claudins (mainly claudin-5), and junctional adhesion molecules; and
cytoplasmic plaque proteins which comprise zonula occludens proteins (ZO-1,
ZO-2) and associated molecules. Formation and maintenance of the TJs are
supported by the presence of adherens junctions which are also composed of
transmembrane and cytoplasmic proteins (the cadherin-catenin and the nectin-
afadin systems). The main cadherin of endothelial cells is VE-cadherin.
Pituitary adenylate cyclase-activating polypeptide (PACAP) was originally
isolated as a hypophysiotropic neuropeptide (Miyata et al. 1989 ). Later it was
shown that it is broadly expressed in the central nervous system and in several
other organs as well, including the retina, kidney, immune cells, reproductive
tissues, gastrointestinal tract, etc. PACAP exerts neuroprotective (Tsuchikawa
et al. 2012 ), cytoprotective, pro-survival (Brown et al. 2013 ),
anti-inflammatory, vasodilator, and several other effects (for review see:
Vaudry et al. 2009 ; Reglodi et al. 2012 ). PACAP has been shown to have
several effects on microvascular endothelia of non-cerebral origin: it protects
mouse hemangioendothelioma cells against the apoptosis-inducing effects of
oxidative stress (Racz et al. 2007 ) and inhibits hyperglycemia-induced
proliferation in H5V murine microvascular endothelial cells (Castorina et al.
2010 ). However, the effects of PACAP on brain endothelial cells are
incompletely understood. It has been shown that PACAP exerts an inhibitory
effect on prostanoid synthesis in rat cerebral microvessels via a cyclic
adenosine monophosphate (cAMP)-dependent pathway (Kis et al. 1999 ). It
has also been shown that PACAP crosses the BBB at a modest degree. The
influx of PACAP into the brain is different between the two isoforms:
PACAP-27 enters the brain by transmembrane diffusion, while PACAP-38 by
a saturable transport system (Banks et al. 1993 ). The peptide transport
system-6 (PTS-6) is responsible for the bidirectional transport of PACAP-38
and for the efflux of PACAP-27 (Dogrukol-Ak et al. 2009 ). On the other
hand, it has not been investigated whether PACAP has any effect on the
barrier properties of the brain endothelium.
Material and Methods
Cell Culture and Treatments
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The human cerebral microvascular endothelial cell line (hCMEC/D3, shortly
D3) (Weksler et al. 2005 ) was cultured on rat tail collagen-coated surfaces in
EBM-2 medium (Lonza) supplemented with 5 % FBS (Lonza) and EGM-2
(Lonza). For immunofluorescence experiments, after reaching confluence,
cells were given 10 mM LiCl for 48 h (Paolinelli et al. 2013 ).
Primary rat brain microvascular endothelial cells (RBECs) were isolated from
2–3-week-old Wistar rats, as described previously (Wilhelm et al. 2007 ;
Hutamekalin et al. 2008 ). Briefly, after removal of meninges, cerebral
cortices were cut into small pieces and digested with 1 mg/ml collagenase
type 2 for 90 min at 37 °C. After separation of myelin by centrifugation in
20 % bovine serum albumin (BSA, Sigma), a second digestion was performed
with 1 mg/ml collagenase/dispase for 50 min at 37 °C. Microvessel fragments
were collected after centrifugation on Percoll gradient (10 min 1,000 g) and
plated onto fibronectin/collagen-coated dishes. Endothelial cells growing out
of the microvessels were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM)/F12, 10 % plasma-derived serum (First Link, UK), and growth
factors. In the first 2 days, 4 µg/ml puromycin was added to remove
contaminating cells. After reaching confluence, the endothelial monolayer
was gently trypsinized and passed onto filter inserts (Transwell-Clear, Costar-
Corning, 1.12 cm , 0.4-µm pore size). The next day, the endothelial
monolayer was supplied with 550 nM hydrocortisone, 250 µM CPT-cAMP,
and 17.5 µM RO-201724.
Rat astrocytes and pericytes were isolated as described previously (Sziraki et
al. 2011 ) and cultured in DMEM (LifeTechnologies) supplemented with 10 %
FBS (Lonza).
Confluent RBEC or D3 monolayers were treated in serum-free DMEM or
glucose-free DMEM (LifeTechnologies) using 100 nM PACAP1-38
(synthesized at the Department of Medical Chemistry, University of Szeged).
For TEER measurements, cells were treated in complete medium, and PACAP
was applied either in the apical/upper or in the basolateral/lower or in both
chambers. DMNQ (2,3-dimethyl-1,4-naphthoquinone; Sigma) was applied in
a concentration of 25 µM.
RT-PCR
Total RNA was extracted from untreated cells using TRIzol reagent
(LifeTechnologies) following the manufacturer’s recommendations. RNA was
2
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transcribed into complementary (c)DNA using a reverse transcription kit
(Thermo Scientific). The amplification was performed on a Bio-Rad iQ5
thermal cycler using Taq polymerase (Roche) under the following conditions:
40 cycles of 95 °C for 15 s, 56 °C for 30 s, and 72 °C for 30 s. Forward and
reverse primers used for the amplification are listed in Table 1 .
Table 1
Primers used
 
Rat primers
 
rPACAP
fw
ATGTCGCCCACGAAATCCTT
 et al.
2012
 
rPACAP
rv
TGTCTGTGAAGATGCCGTCC
 rPAC1
fw AAATGCTACTGCAAGCCACA
 rPAC1
rv
GCTCTTGCTCAGGATGGACA
 
rVPAC1
fw
GTGAAGACCGGCTACACCAT
 
rVPAC1
rv
TGAAGAGGGCCATATCCTTG
 
rVPAC2
fw
AGAGCCATCTCTGTGCTGGT
 
rVPAC2
rv
AGGTAGGCCAGGAAACACCT
Human primers
 
hPACAP
fw
CGGGAGGAGTTGAAGGAATGA
 et al.
2006
 
hPACAP
rv
GACAGCCATTTGTTTCCGGT
 hPAC1
fw AGCATCTACTTCAGCTGCGTG
Giunta In table 1 this
reference refers to the last 4 rows
(rVPAC1 fw, rVPAC1 rv, rVPAC2 fw
and rVPAC2 rv) and not to the
whole set of rat primers.
Basille In table 1 this
reference refers to the last 4 rows
(hVPAC1 fw, hVPAC1 rv, hVPAC2 fw
and hVPAC2 rv) and not to the
whole set of human primers.
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  hPAC1
rv
TTCCAGCTTCGCCATTTTCG
 
hVPAC1
fw
ATGTGCAGATGATCGAGGTG
 
hVPAC1
rv
TGTAGCCGGTCTTCACAGAA
 
hVPAC2
fw
CTTCAGGAAGCTGCACTGC
 
hVPAC2
rv
CAAACACCATGTAGTGGACG
Determination of Apoptosis
D3 monolayers were treated in serum-free DMEM or glucose-free DMEM
with 25 µM DMNQ and/or 100 nM PACAP for 90 min. Apoptotic cells were
stained with anti-cleaved caspase 3 antibody (Cell Signaling). Simultaneously
with the secondary antibody, 0.6 µg/ml Hoechst-33342 was added for marking
the nuclei. The number of apoptotic cells was compared to the total cell
number. We have also analyzed the expression profile of apoptosis-related
proteins using a human apoptosis array kit (R&D Systems) according to the
manufacturer’s instructions.
Measurement of Transendothelial Electrical Resistance
RBECs were grown on semipermeable filters (as described) and placed into
the wells of the cellZscope® instrument (nanoAnalytics). Cells were treated
with PACAP when the TEER had reached plateau (i.e., the monolayer has
reached total confluence and mature junctions have been formed). TEER was
afterwards monitored for 4 h.
Immunofluorescence
For immunofluorescence studies, cells were cultured on 96-well plates. Brain
endothelial monolayers were fixed using a mixture of ice cold ethanol/acetic
acid (95:5) for 5 min and then washed three times for 5 min in phosphate-
buffered saline (PBS). After blocking with 3 % BSA for 30 min, the
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monolayers were incubated with primary antibodies against occludin
(LifeTechnologies), claudin-5 (LifeTechnologies), VE-cadherin (Santa Cruz),
or ZO-1 (LifeTechnologies). After washing, Cy3- or Alexa488-conjugated
secondary antibodies (Jackson ImmunoResearch) were applied, followed by a
second washing step. Distribution of the signal was studied using a Nikon
Eclipse TE2000U photomicroscope with epifluorescent capabilities connected
to a digital camera (Spot RT KE, Diagnostic Instruments).
Western-Blot Analysis
Cells were washed with PBS and scraped into ice-cold
radioimmunoprecipitation assay (RIPA) lysis buffer (20 mM Tris (pH = 7.4),
150 mM NaCl, 1 % sodium deoxycholate, 0.1 % sodium dodecyl sulfate,
1 mM sodium vanadate, 10 mM NaF, 1 mM Pefabloc) and incubated on ice
for 30 min. Lysates were clarified by centrifugation at 10,000 g for 10 min on
4 °C. The protein concentration of the supernatants was determined with the
bicinchoninic acid (BCA) method (Pierce). Samples were mixed with
Laemmli buffer (final concentration: 12 mM Tris-HCl (pH = 6.8), 5 %
glycerol, 0.4 % sodium dodecyl sulfate, 14.4 µM 2-mercaptoethanol, 0.02 %
bromophenol blue) and boiled for 3 min. Proteins were electrophoresed with
standard denaturing SDS-PAGE procedures and blotted on nitrocellulose
membranes (Protran or Bio-Rad). Blocking the non-specific binding capacity
of the membranes was carried out at room temperature for 30 min in TBS-T
(Tris buffered saline with 0.1 % Tween 20) containing 3 % BSA or 5 % casein
(non-fat milk powder). Blots were then incubated with the primary antibodies.
After washing the membranes three times for 10 min in TBS-T, blots were
incubated with the secondary antibodies (Pierce), then washed again three
times for 10 min in TBS-T. The immunoreaction was visualized using
Immobilon Western Chemiluminescent HRP Substrate (Millipore) on X-ray
film (Agfa). Densitometric analysis was performed using the ImageJ software.
Results
Characterization of the Expression of PACAP and PACAP
Receptors on Cells Forming the BBB
First we studied the expression of PACAP and its receptors on brain
endothelial cells (primary rat brain microvascular endothelial cells and the
human microvascular cerebral endothelial cell line D3) using reverse
transcriptase polymerase chain reaction (RT-PCR). In order to avoid false
positive results originating from genomic contamination, all primer pairs were
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designed from different exons (Table 1 ). As shown on Fig. 1 , we found the
presence of PACAP and VPAC2 messenger (m)RNA in both types of brain
endothelial cells analyzed and VPAC1 in the human endothelial cell line.
PAC1 receptor was expressed neither in rat nor in human brain endothelial
cells. We have also analyzed the expression of PACAP and PACAP receptors
on other cells associated with the BBB. Astrocytes expressed PACAP and all
the three receptors, while in pericytes we could detect the mRNA of VPAC2
and low amounts of PAC1 and VPAC1.
Fig. 1
Expression of PACAP and PACAP receptors on cells of the BBB. RT-PCR was
performed using cDNA isolated from primary RBECs, rat astrocytes and
pericytes, and the human cerebral endothelial cell line D3. One representative of
three independent experiments (in case of primary cells: of three independent
cell isolations) is shown. Positive controls: rat brain and human tonsil, negative
controls: non-template reactions
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Effect of PACAP on the Survival of Brain Endothelial Cells
Since PACAP was shown to attenuate apoptosis in mouse
hemangioendothelioma (Racz et al. 2007 ) and several other cell types
(Seaborn et al. 2011 ), we wanted to test whether PACAP also had
anti-apoptotic effect in brain endothelial cells. We examined cells exposed to
glucose deprivation and/or oxidative stress (using DMNQ) treated or not with
100 nM PACAP1-38. Apoptosis was detected using immunostaining of
cleaved caspase 3 positive cells (Fig. 2a ) and an antibody array (Fig. 2b  and
Suppl. Fig. 1B ). Although clear morphological changes and cell death were
detected (Suppl. Fig. 1A ), we have observed only a slight induction of the
number of apoptotic cells and apoptotic markers in response to glucose
deprivation and oxidative stress. Our results showed that PACAP had no
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significant anti-apoptotic or pro-survival effect in cerebral endothelial cells
(Fig. 2  and Suppl. Fig. 1 ).
Fig. 2
Evaluation of apoptosis in brain endothelial cells. D3 cells were exposed to
glucose deprivation- and/or DMNQ-induced oxidative stress in the absence or
presence of 100 nM PACAP. a Cleaved caspase 3 positive cells were counted
and compared to the total number of nuclei. b Cell lysates were applied onto the
human apoptosis array kit. Quantitative analysis of the data is shown on Suppl.
Fig. 1B
Effect of PACAP on the Junctional Complex of Brain
Endothelial Cells
Our main goal, however, was to understand whether PACAP influenced the
tight and adherens junctions of cerebral endothelial cells. Therefore, we
measured the transendothelial electrical resistance (TEER), which is a very
sensitive marker of the paracellular barrier. PACAP1-38 induced a marked
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increase in TEER when applied in the apical (upper) compartment, but no
effect was observed when applied in the basolateral (lower) compartment
(Fig. 3 ). The effect appeared immediately after administration: PACAP
attenuated the medium change-induced TEER drop and maintained the TEER
at higher levels in comparison to the control. When applied to both the apical
and the basolateral side or when lower PACAP concentrations were
administered (not shown), the effect was slighter and lasted for a shorter time.
Fig. 3
Effect of PACAP on the TEER of cerebral endothelial cells. RBECs were
cultured on semipermeable filter inserts. PACAP was applied in a concentration
of 100 nM either in the upper, lower, or both (u + l) compartments. TEER was
monitored using the cellZscope® system. Values are % control at start of the
experiment, representing average ± SD. *p < 0.05 as assessed by ANOVA and
Bonferroni’s post hoc test (red indicates PACAP upper vs. control, violet
indicates PACAP u + l vs. control). One representative of three independent
experiments is presented
As a next step, we examined whether PACAP had a protective effect on the
disassembly of the junctions induced by different pathological conditions.
Glucose deprivation and DMNQ-induced oxidative stress alone or in
combination induced the disruption of the continuous membrane staining of
the junctional proteins ZO-1, VE-cadherin, occludin, and claudin-5 (Fig. 4
and Suppl. Fig. 2 ). In the presence of glucose deprivation or DMNQ-induced
oxidative stress, we observed several holes on the membrane staining. When
glucose deprivation and oxidative stress were applied concomitantly, we
observed an almost total disappearance of the transmembrane junctional
proteins from the cell membranes. Arrows in Fig. 4  and Suppl. Fig. 2  point to
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the discontinuities in the membrane staining. Transmembrane proteins
(VE-cadherin, occludin, and claudin-5) were more sensitive to stress-induced
disruption than the cytoplasmic protein ZO-1.
Fig. 4
a–d Effect of PACAP on the localization of tight and adherens junction
proteins. RBECs or D3 cells were exposed to glucose deprivation- and/or
DMNQ-induced oxidative stress in the absence or presence of 100 nM PACAP.
Immunofluorescence stainings were performed using anti-ZO-1 or anti-VE-
cadherin antibodies. Junctional disruption (indicated by arrows) is represented
by the discontinuity or disappearance of the membrane staining. One
representative of three independent experiments is presented
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PACAP treatment alone induced a stronger junctional staining of claudin-5,
occludin (Suppl. Fig. 2 ), ZO-1, and VE-cadherin (Fig. 4 ) in RBECs. The
same effect was seen in D3 cells which do not form such a tight barrier as
primary cells (Fig. 4 ). Moreover, PACAP had a protective effect on glucose
deprivation- and/or DMNQ-induced junctional disassembly in both RBECs
and D3 cells, i.e., no or less holes could be observed on the membrane
stainings and the territories with absent membrane staining were much
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smaller. PACAP treatment could almost totally maintain the continuity of the
tight and adherens junctions in glucose-free conditions in both brain
endothelial cell types analyzed and could significantly improve the
DMNQ-induced junctional disassembly. When glucose deprivation and
oxidative stress were applied concomitantly, we observed an almost total
disappearance of the transmembrane junctional proteins from the cell
membranes and a severe disruption of the ZO-1 staining. PACAP could partly
reverse these effects (Fig. 4 ).
To test whether PACAP influenced not only the localization but also the
expression of the junctional proteins, we performed Western-blot experiments.
Our results indicated that PACAP did not significantly induce the expression
of tight and adherens junction proteins in RBECs or D3 cells (Fig. 5  and
Suppl. Fig. 3 ). Only the amount of occludin increased in D3 cells, but not in
the tight barrier forming RBECs. We observed a decrease in the amount of
ZO-1 protein in response to glucose-free conditions combined with DMNQ;
however, this was not affected by PACAP.
Fig. 5
Effect of PACAP on the expression of tight and adherens junction proteins.
RBECs or D3 cells were exposed to glucose deprivation- and DMNQ-induced
oxidative stress in the absence or presence of 100 nM PACAP. Western-blot
experiments were performed using the RIPA-soluble fractions. β-Actin was used
as a loading control. One representative of three independent experiments is
presented. Quantitative analysis is shown on Suppl. Fig. 3
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Discussion
Pituitary adenylate cyclase-activating polypeptide and its receptors have been
shown to have widespread distributions in organism. However, the expression
of PACAP and PACAP receptors on cells of the BBB has not been
investigated so far, except for astrocytes, which have been shown to express
PACAP, PAC1, VPAC1, and VPAC2 (Grimaldi and Cavallaro 1999 ; Jaworski
2000 ). In accordance with literature data, we showed the presence of PACAP
and its three receptors on astrocytes. Additionally, we observed the presence
of VPAC2 and low amounts of PAC1 and VPAC1 in brain pericytes. We also
showed that microvascular cerebral endothelial cells expressed PACAP. In
accordance, isolated brain microvessels have been shown to release PACAP,
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which is decreasing with age (Tripathy et al. 2012 ).
We also detected VPAC2 in cerebral endothelial cells, while VPAC1 was
present only in human, but not in rat brain endothelial cells. We have observed
that PACAP treatment induced a marked increase in TEER when applied in
the apical (upper) compartment. This suggests that PACAP receptors are
probably present in the apical and not in the basolateral membrane. The two
membrane parts are divided by the tight junctions which prevents the
diffusion of proteins and lipids between the apical and the basolateral
membranes. Interestingly, in the rat middle cerebral artery, all three PACAP
receptors were found to be present and abluminal but not luminal VIP,
PACAP-27, and PACAP-38 caused concentration-dependent arterial
relaxations (Erdling et al. 2013 ), underlying the difference between
macrovascular and BBB-forming microvascular brain endothelial cells.
According to our results, PAC1 was present neither in human nor in rat brain
microvascular endothelial cells. Since most of the anti-apoptotic effects of
PACAP are mediated through the PAC1 receptor (Seaborn et al. 2011 ), the
absence of PAC1 from our cells may explain the lack of a significant
pro-survival effect of PACAP on cerebral microvascular endothelial cells.
Interestingly, although in response to glucose deprivation and oxidative stress
marked cell death was observed (Suppl. Fig. 1A ), this was not accompanied
by the induction of apoptotic markers. This suggests that another type of cell
death occurred (e.g., necrosis); however, we did not investigate in details the
molecular processes leading to cell death. Nevertheless, glucose deprivation-
and/or oxidative stress-induced brain endothelial cell death was not reversed
by the presence of PACAP.
The interaction of PACAP with the cerebral endothelium is far from being
well-understood and mainly restricted to macrovessels. PACAP-27 and
PACAP-38 were shown to be potent vasodilators in porcine neonatal pial
vessels and rat middle cerebral artery (Lenti et al. 2007 ; Erdling et al. 2013 ).
On the other hand, the effects of PACAP on microvascular brain endothelial
cells, which form the BBB, are not well-characterized. High concentrations of
PACAP (10 nM–1 µM) were shown to significantly inhibit the activity of the
cyclooxygenase pathway in isolated cerebral microvessels (Kis et al. 1999 ).
However, the effects of PACAP on the barrier properties of the brain
endothelium have not been investigated so far.
Capillary endothelial cells of the brain parenchyma form a restrictive
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paracellular barrier by the presence of well-developed tight junctions. cAMP
is known to increase the transendothelial electrical resistance (TEER), which
is the most important marker of the tightness of the TJs (for review see:
Krizbai and Deli 2003 ). Intracellular cAMP is known to strengthen the barrier
function of the cerebral endothelium (Stelzner et al. 1989 ; Rubin et al. 1991 ;
Rubin and Staddon 1999 ; Ishizaki et al. 2003 ). Moreover, cAMP-elevating
agents, like adrenomedullin or cilostazol have also been shown to stabilize the
tight junctions of cerebral endothelial cells (Kis et al. 2001 ; Horai et al.
2013 ). Nevertheless, all three receptors of PACAP (PAC1, VPAC1, and
VPAC2) signal mainly through the cAMP/PKA pathway. Hence, we have
focused our investigations on the potential effects of PACAP on the TJs of
cerebral endothelial cells.
Our results show that PACAP stabilizes the junctional proteins in the
membrane of brain endothelial cells in both control and pathological
conditions. cAMP has been shown to induce the expression and
phosphorylation of claudin-5 through different mechanisms and to enhance
signals of claudin-5, occludin, ZO-1, ZO-2, and VE-cadherin along cell
boundaries (Ishizaki et al. 2003 ). PACAP had no effect on the expression of
the junctional proteins; however, the membrane staining of several tight and
adherens junction proteins increased significantly, suggesting that PACAP
induces junctional proteins to localize to the intercellular contacts.
In summary, this is the first report that PACAP improves the function of the
tight junctions of cerebral endothelial cells without affecting their survival.
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Supplementary Fig. 1
Effect of PACAP on the survival of cerebral endothelial cells. D3 cells were
exposed to glucose-deprivation and DMNQ-induced oxidative stress in the
absence or presence of 100 nM PACAP. A: Phase contrast images showing the
morphological changes. B: Densitometric analysis of pro-caspase 3 and the
pro-apoptotic proteins Bad, Bax and cleaved caspase 3 from the apoptosis array
presented on Fig. 2b . (JPEG 88 kb)
High resolution image (TIFF 18790 kb)
Supplementary Fig. 2
Effect of PACAP on the localization of tight junction proteins. RBECs were
exposed to glucose-deprivation and/or DMNQ-induced oxidative stress in the
absence or presence of 100 nM PACAP. Immunofluorescence stainings were
performed using anti-occludin or anti-claudin-5 antibodies. Junctional
disruption (indicated by arrows) is represented by the discontinuity or
disappearance of the membrane staining. One representative of three
independent experiments is presented. (JPEG 67 kb)
High resolution image (TIFF 18790 kb)
Supplementary Fig. 3
Effect of PACAP on the expression of tight and adherens junction proteins.
RBECs or D3 cells were exposed to glucose-deprivation and DMNQ-induced
oxidative stress in the absence or presence of 100 nM PACAP. Western-blot
experiments were performed using the RIPA-soluble fractions. Densitometric
analysis of three independent experiments is presented. **: p < 0.05, *: p < 0.01
compared to control, ##: p < 0.05 compared to G-free + DMNQ, as assessed by
e.Proofing http://eproofing.springer.com/printpage.php?token=GAdkHsZ-KwYI...
18 of 22 2014.07.17. 11:18
ANOVA and Bonferroni’s post hoc test. (JPEG 7 kb)
High resolution image (TIFF 2196 kb)
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